The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. …”

Percentage of exhale flux penetrating through the mask fabric for different values of <i>c</i>_<i>k</i>; a–c and d–f decreasing porosity for outward and inward protection... by Akshay Anand (118579)

Participant demographics. * P-values were determined using Fisher-Freeman-Halton test when contingency tables are larger than 2 × 2. by Elie Mulhem (22537863)

Subjects:

Loss of ECRG4 expression decreases neutrophil mobilization from bone marrow reserves. by Katie D. Pool (20141584)

Subjects:

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes by Shakkira Erimban (6882539)

Subjects:

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes by Shakkira Erimban (6882539)

Subjects:

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. by Peiqi Yin (6533747)

Contribution of the through-mask leakages from the cavity and channel network distributed along the periphery of the mask; a–c and d–f are decreasing porosity <i>c</i><sub><i>k</i>... by Akshay Anand (118579)

Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive... by Elie Mulhem (22537863)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: